Collection's Items (Sorted by Submit Date in Descending order): 1 to 20 of 182
| Preview | Issue Date | Title / Name | Author(s) |
| Mar-2026 | High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD) | Nair-Shalliker, V.; Smith, D. P.; Gebski, V.; Patel, M. I.; Frydenberg, M.; Yaxley, J.; Gardiner, R.; Espinoza, D.; Kimlin, M. G.; Dhillon, V.; Leifert, W.; Gillatt, D.; Woo, H.; Rasiah, K.; Awad, Nader; Symons, J.; Wells, J. K.; Pickett, M.; French, M.; Anderson, P. H.; Armstrong, B. K.; Gurney, H.; Awad, Nader | |
| Feb-2026 | Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304) | Inderjeeth, A-J.; Martin, A.J.; Zielinski, R.R.; Begbie, S.; Cheung, L.; Chowdhury, S.; Frydenberg, M.; Horvath, L.G.; Joshua, A.M.; Lawrence, N.J.; Marx, G.; McCaffrey, J.; McDermott, R.S.; McJannett, M.; North, S.A.; Parnis, F.; Parulekar, W.R.; Pook, D.W.; Reaume, M.N.; Sandhu, S.; Tan, A.; Tan, T.H.; Thomson, A.H.; Vera-Badillo, F.; Williams, S.G.; Thomas, H.; Yip, S.; Zhang, A.Y.; Chi, K.N.; Stockler, M.R.; Sweeney, C.J.; Davis, I.D.; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.; Begbie, Stephen D. | |
| Mar-2026 | High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD) | Nair-Shalliker, V.; Smith, D.P.; Gebski, V.; Patel, M.I.; Frydenberg, M.; Yaxley, J.; Gardiner, R.; Espinoza, D.; Kimlin, M.G.; Dhillon, V.; Leifert, W.; Gillatt, D.; Woo, H.; Rasiah, K.; Awad, N.; Symons, J.; Wells, J.K.; Pickett, H.A.; Fenech, M.; Anderson, P.H.; Armstrong, B.K.; Gurney, H.; Awad, Nader | |
| Nov-2025 | Definitive Chemoradiotherapy for Oesophageal Cancer: a Retrospective Institutional Review | Freeman, Georgia; Lo, Helen; Last, Andrew; Roach, Ethan; Freeman, Georgia; Lo, Helen | |
| Oct-2025 | Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: Ten-year results for intermediate- and high-risk prostate cancer patients | Armstrong, A.; McLachlan, C.; Li, A.; Wilcox, S.; Vettivelu, H.; Armstrong, S.; Shakespeare, T. P.; Vettivelu, Haripriya; Shakespeare, Thomas P. | |
| 13-Jun-2025 | Validation of a weekly imaging protocol for tangential whole breast radiation therapy with a tattoo-less surface-guided setup | Namba, S.; Steel, J.; Hoffmann, M.; Thompson, H.; Baylis, A.; Hansen, C.; Shakespeare, T.; Namba, Sumie; Steel, Jared G.; Hoffmann, Matthew; Thompson, Hannah; Baylis, Abbey; Hansen, Carmen; Shakespeare, Thomas P. | |
| 8-Aug-2025 | Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer | Mehra, N.; Antonarakis, E. S.; Park, S. H.; Goh, J. C.; McDermott, R.; Gonzalez, N. S.; Fong, P. C.; Griel, R.; De Santis, M.; Yanez, P. E.; Huang, Y. H.; Begbie, S. D.; Rey, F.; Kramer, G.; Suzuki, H.; Saretsky, T. L.; Ghate, S. R.; Cui, Y.; Hosius, C.; Yu, E. Y.; Begbie, Stephen | |
| Jul-2025 | Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors | Anderson, M. A.; Awan, F. T.; Berkahn, L.; Crassini, K.; Lee, H.; Marlton, P.; Mulligan, S. P.; Nolan, M.; Tam, C.; Sverdlov, A.; Crassini, Kyle | |
| Sep-2025 | Validation of a weekly imaging protocol for tangential whole breast radiation therapy with a tattoo-less surface-guided setup | Namba, S.; Steel, J.; Hoffmann, M.; Thompson, H.; Baylis, A.; Hansen, C.; Shakespeare, T.; Namba, Sumie; Steel, Jared G.; Hoffmann, Matthew; Thompson, Hannah; Baylis, Abbey; Hansen, Carmen; Shakespeare, Thomas P. | |
| Jun-2025 | Primary Cutaneous SMARCA4-Deficient Tumor With Metastases | Pradhan, S.; Lehman, M.; Tahir, A. M.; Su, M.; Kossard, S.; Sakalkale, R.; Tahir, Abdul R. M.; Su, Michael | |
| Feb-2025 | Be smart about SMARC(A4) | Pradhan, S.; Lehman, M; Tahir, A. R.; Su, M.; Sakalkale, R.; Pradhan, Supriya; Tahir, Abdul R. M.; Su, Michael; Sakalkale, Renukadas | |
| Feb-2025 | A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study). | Crumbaker, M.; Shekar, S.; Lawrence, M.G.; Goldstein, L. G.; Yam, A. O.; Downton, T.; Begbie, S.; Zielinski, R.; Fox, W.; Araiza, N.; Yousif, J.; Ratnayake, L.; Antonarakis, E. S.; Denmeade, S. R.; Joshua, A. M.; Begbie, Stephen; Fox, William | |
| Feb-2022 | Evaluation of apical clips placed during axillary dissection demonstrates potential under‐coverage of axillary radiation therapy target volumes during breast cancer regional nodal irradiation | Hsieh, M.T.; Aherne, N.J.; Westhuyzen, J.; Winkley, L.; Shakespeare, T.P.; Ross, W.; Salindera, S.; Hsieh, M.T.; Aherne, Noel; Westhuyzen, Justin; Winkley, Lauren; Shakespeare, Thomas P.; Ross, William; Salindera, S. | |
| Sep-2014 | Planning magnetic resonance imaging for prostate cancer intensity-modulated radiation therapy: Impact on target volumes, radiotherapy dose and androgen deprivation administration | Horsley, P.J.; Aherne, N.J.; Edwards, G.V.; Benjamin, L.C.; Wilcox, S.W.; Welshman, R.; Mckay, M.; Shakespeare, T.P.; Mclachlan, C.S.; Assareh, H.; Horsley, Patrick J.; Aherne, Noel; Edwards, Grace V.; Benjamin, Linus C.; Wilcox, Shea; Welshman, R.; McKay, Michael J.; Shakespeare, Thomas P.; Mclachlan, C.S. | |
| Mar-2025 | Update of clinical practice guidelines for the management of patients with sarcoma | Gyorki, D. E.; Bae, S.; Smith, R. C.; Caruso, D. A.; Coker, D.; Connolly, E. A.; Desai, J.; Johnston, A.; Lawless, K. A.; Lazarakis, S.; Lo, H.; Maclean, F.; Mar, J.; McDonough, J.; Perianayagam, G.; Phillips, M.; Pryor, D.; Sundaram, A.; Thompson, S. R.; Zhou, D. D-X.; Hong, A. M.; Lo, Helen | |
| Sep-2023 | Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial | Friedlander, M.; Mileshkin, L.; Lombard, J.; Frentzas, S.; Gao, B.; Wilson, M.; Meniawy, T.; Baron-Hay, S.; Briscoe, K.; McCarthy, N.; Fountzilas, C.; Cervantes, A.; Ge, R.; Wu, J.; Spira, A.; Briscoe, Karen | |
| Aug-2021 | Implementation of the Australian Computer-Assisted Theragnostics (AusCAT) network for radiation oncology data extraction, reporting and distributed learning | Field, M.; Vinod, S.; Aherne, N.; Carolan, M.; Dekker, A.; Delaney, G.; Greenham, S.; Hau, E.; Lehmann, J.; Ludbrook, J.; Miller, A.; Rezo, A.; Selvaraj, J.; Sykes, J.; Holloway, L.; Thwaites, D.; Aherne, Noel; Greenham, Stuart | |
| Jul-2021 | Machine learning applications in radiation oncology | Field, M.; Hardcastle, N.; Jameson, M.; Aherne, N.; Hollway, L.; Aherne, Noel | |
| Dec-2014 | Prevalence of complementary and alternative therapy use by cancer patients undergoing radiation therapy | Edwards, G. V.; Aherne, N. J.; Horsley, P.; Benjamin, L. C.; McLachlan, C. S.; McKay, M. J.; Shakespeare, T. P.; Edwards, Grace V.; Aherne, Noel; Horsley, Patrick J.; Benjamin, Linus C.; McLachlan, Craig S.; McKay, Michael J.; Shakespeare, Thomas P. | |
| Dec-2016 | Rural radiation therapy ine(quality): Time to bust an urban myth | Dwyer, P. M.; Aherne, N. J.; Tahir, A. R.; Hill, J.; Masoud-Rahbari, R.; Shakespere, T. P.; Aherne, Noel; Tahir, Abdul R. M.; Hill, Jacques; Shakespeare, Thomas P. | |
Collection's Items (Sorted by Submit Date in Descending order): 1 to 20 of 182